m 6 A‐dependent upregulation of DDX21 by super‐enhancer‐driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia
Clinical and Translational Medicine · 2024
DOI: 10.1002/ctm2.1628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2024. Verfasst von Yanchun Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Nuclear Proteins. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Research Project of Jinan Microecological Biomedicine Shandong Laboratory, Key Research and Development Program of Zhejiang.
Abstract (Originalsprache)
Background
Acute myeloid leukaemia (AML) is a haematological malignancy with unfavourable prognosis. Despite the effectiveness of chemotherapy and targeted therapy, relapse or drug resistance remains a major threat to AML patients. N6‐methyladenosine (m 6 A) RNA methylation and super‐enhancers (SEs) are extensively involved in the leukaemogenesis of AML. However, the potential relationship between m 6 A and SEs in AML has not been elaborated.
Methods
Chromatin immunoprecipitation (ChIP) sequencing data from Gene Expression Omnibus (GEO) cohort were analysed to search SE‐related genes. The mechanisms of m 6 A‐binding proteins IGF2BP2 and IGF2BP3 on DDX21 were explored via methylated RNA immunoprecipitation (MeRIP) assays, RNA immunoprecipitation (RIP) assays and luciferase reporter assays. Then we elucidated the roles of DDX21 in AML through functional assays in vitro and in vivo. Finally, co‐immunoprecipitation (Co‐IP) assays, RNA sequencing and ChIP assays were performed to investigate the downstream mechanisms of DDX21.
Results
We identified two SE‐associated transcripts IGF2BP2 and IGF2BP3 in AML. High enrichment of H3K27ac, H3K4me1 and BRD4 was observed in IGF2BP2 and IGF2BP3, whose expression were driven by SE machinery. Then IGF2BP2 and IGF2BP3 enhanced the stability of DDX21 mRNA in an m 6 A‐dependent manner. DDX21 was highly expressed in AML patients, which indicated a poor survival. Functionally, knockdown of DDX21 inhibited cell proliferation, promoted cell apoptosis and led to cell cycle arrest. Mechanistically, DDX21 recruited transcription factor YBX1 to cooperatively trigger ULK1 expression. Moreover, silencing of ULK1 could reverse the promoting effects of DDX21 overexpression in AML cells.
Conclusions
Dysregulation of SE‐IGF2BP2/IGF2BP3‐DDX21 axis facilitated the progression of AML. Our findings provide new insights into the link between SEs and m 6 A modification, elucidate the regulatory mechanisms of IGF2BP2 and IGF2BP3 on DDX21, and reveal the underlying roles of DDX21 in AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.
- Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China.
- Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.
- Jinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong, China.
ORCID-Profile: Jie Jin
Förderung
- National Natural Science Foundation of China
- Research Project of Jinan Microecological Biomedicine Shandong Laboratory
- Key Research and Development Program of Zhejiang
Zitieren
APA
Zhao, Y., Zhou, Y., Qian, Y., Wei, W., Lin, X., Mao, S., Sun, J., & Jin, J. (2024). m 6 A‐dependent upregulation of DDX21 by super‐enhancer‐driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1628
Vancouver
Zhao Y, Zhou Y, Qian Y, Wei W, Lin X, Mao S, et al. m 6 A‐dependent upregulation of DDX21 by super‐enhancer‐driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia. Clinical and Translational Medicine. 2024. doi:10.1002/ctm2.1628
BibTeX
@article{Zhao2024,
author = {Zhao, Yanchun and Zhou, Yutong and Qian, Yu and Wei, Wenwen and Lin, Xiangjie and Mao, Shihui and Sun, Jie and Jin, Jie},
title = {m 6 A‐dependent upregulation of DDX21 by super‐enhancer‐driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia},
journal = {Clinical and Translational Medicine},
year = {2024},
doi = {10.1002/ctm2.1628}
}
EUVIMED